Technology Commercialization Office

Showing 26 result(s) for "Healthcare Portfolios"

A treatment for spinal muscular atrophy.

A novel method using the overexpression of survival motor neuron protein to improve motor unity synaptic repair and restore/protect muscle size and function due to sarcopenia.

Inh2-B1 serves as a therapeutically important “antibiotic-resistance-breaker,” which enhances the bactericidal activity of Ceftriaxone/Cefotaxime against highly pathogenic MDRSA infection.

A combination-therapy that has the potential to overcome and/or prevent the commonly observed acquisition of sorafenib resistance, which is associated with treatment failure in patients with hepatocellular carcinoma.

Self-assembling, highly stable RNA cages amenable to custom functionalization and cargo delivery

An efficient delivery vehicle for therapeutic oligonucleotides with high efficiency.

A molecular tool for predicting risk of local and regional recurrence of pancreatic adenocarcinoma.

Ohio State University researchers have discovered novel subset of human CD34 (+) hematopoietic precursor cells and generated a method of isolating them.

Combined treatment of plerixafor and Flt3L better mobilize stem cells and do not exacerbate graft-versus-host disease following transplatation.

Parthenolide analogues derived from plants could be effective in treating leukemia or supplementing other treatments.